Today: NantHealth Inc (NH) Upgraded at Zacks Investment Research

Today: NantHealth Inc (NH) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of NantHealth Inc (NYSE:NH) from a sell rating to a hold rating in a research report released on Wednesday morning.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

Several other research firms have also commented on NH. Canaccord Genuity restated a buy rating and issued a $17.00 price objective on shares of NantHealth in a research note on Monday, September 19th. Cowen and Company initiated coverage on NantHealth in a research note on Monday, June 27th. They issued an outperform rating and a $19.00 price target for the company. FBR & Co initiated coverage on NantHealth in a research note on Monday, June 27th. They issued an outperform rating and a $18.00 price target for the company. First Analysis initiated coverage on NantHealth in a research note on Monday, June 27th. They issued an overweight rating and a $18.00 price target for the company. Finally, Jefferies Group initiated coverage on NantHealth in a research note on Monday, June 27th. They issued a buy rating for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. NantHealth presently has an average rating of Buy and an average target price of $18.00.

NantHealth (NYSE:NH) traded down 0.94% on Wednesday, hitting $12.67. The stock had a trading volume of 313 shares. NantHealth has a 52-week low of $9.79 and a 52-week high of $16.63. The firm’s market cap is $1.54 billion. The company’s 50 day moving average price is $13.21 and its 200 day moving average price is $12.70.

NantHealth (NYSE:NH) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.26. The company earned $31.50 million during the quarter, compared to analysts’ expectations of $23.55 million. The business’s revenue for the quarter was up 166.9% on a year-over-year basis. Analysts expect that NantHealth will post ($0.59) EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wildcat Capital Management LLC bought a new position in NantHealth during the second quarter valued at approximately $3,008,000. Jefferies Group LLC bought a new position in NantHealth during the second quarter valued at approximately $6,943,000. Blackstone Group L.P. bought a new position in NantHealth during the second quarter valued at approximately $7,463,000. Finally, FMR LLC bought a new position in NantHealth during the second quarter valued at approximately $11,250,000.

NantHealth Company Profile

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Related posts

Leave a Comment